5 Result(s)

Article

Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma

Mantle cell lymphoma (MCL) is a lethal hematological malignancy with a median survival of 4 years. Its lethality is mainly attributed to a limited understanding of clinical tumor progression and resistance to ...

Anuvrat Sircar, Satishkumar Singh, Zijun Y. Xu-Monette, Krysta Mila Coyle… in Leukemia (2023)

Article

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents

Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment app...

Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury… in Journal of Hematology & Oncology (2023)

Article

A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells

Mantle cell lymphoma (MCL) is a rare, highly heterogeneous type of B-cell non-Hodgkin’s lymphoma. The sumoylation pathway is known to be upregulated in many cancers including lymphoid malignancies. However, li...

Walter Hanel, Pushpa Lata, Youssef Youssef, Ha Tran… in Experimental Hematology & Oncology (2022)

Article

Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia

Carolina Vicente-Dueñas, Inés González-Herrero, Lalit Sehgal… in Leukemia (2019)

Article

Targeting Wnt pathway in mantle cell lymphoma-initiating cells

Mantle cell lymphoma (MCL) is an aggressive and incurable form of non-Hodgkin’s lymphoma. Despite initial intense chemotherapy, up to 50 % of cases of MCL relapse often in a chemoresistant form. We hypothesize...

Rohit Mathur, Lalit Sehgal, Frank K. Braun… in Journal of Hematology & Oncology (2015)